POPULARITY
37 episodes with Amyloid
9 episodes with Amyloid
6 episodes with Amyloid
42 episodes with Amyloid
7 episodes with Amyloid
4 episodes with Amyloid
7 episodes with Amyloid
4 episodes with Amyloid
7 episodes with Amyloid
4 episodes with Amyloid
7 episodes with Amyloid
3 episodes with Amyloid
5 episodes with Amyloid
4 episodes with Amyloid
3 episodes with Amyloid
4 episodes with Amyloid
4 episodes with Amyloid
5 episodes with Amyloid
8 episodes with Amyloid
3 episodes with Amyloid
7 episodes with Amyloid
5 episodes with Amyloid
2 episodes with Amyloid
3 episodes with Amyloid
3 episodes with Amyloid
3 episodes with Amyloid
2 episodes with Amyloid
This episode is for every woman who has watched a loved one battle Alzheimer's and wondered, "Is there anything I can do to prevent this?" The answer is yes.In part three of our four-part series on Alzheimer's prevention, we explore the latest pharmaceutical breakthroughs, the three-phase model of Alzheimer's progression, and why early intervention is everything.Tune in to discover what treatments are available, what's in the research pipeline, and how to evaluate options for yourself or a loved one.What to Listen For:[02:00] – The difference between treating Alzheimer's symptoms vs. modifying the disease itself[04:30] – The 3-phase model of Alzheimer's progression and why it matters for treatment[07:00] – The crucial difference between early-onset and late-onset Alzheimer's[10:45] – Dr. Rudy Tanzi's “sink metaphor” for how Alzheimer's develops in the brain[13:00] – The first-ever fully FDA-approved drugs to slow cognitive decline[15:30] – Who qualifies for these new Alzheimer's drugs—and who doesn't[17:00] – The serious risks and side effects of monoclonal antibody treatments[20:15] – Why these drugs only work in the early stages of Alzheimer's[22:00] – The staggering cost of new treatments and what insurance may (or may not) cover[25:00] – The future of Alzheimer's treatment: What's in the research pipeline right nowEarly is everything. This episode has covered the latest in Alzheimer's treatments, but the most important takeaway is that early intervention gives you the most options. Whether through lifestyle changes, early screenings, or new pharmaceutical breakthroughs, there are steps you can take today to protect your brain health.If this episode resonated with you, be sure to subscribe to Happy and Healthy with Amy Lang, and check out the links below for more resources!From The EpisodeEpisode 274: The Latest Alzheimer's Treatments (2025 Update)RESOURCES: Book a FREE Discovery Call with Amy Lang Order Amy's book Thoughts Are Habits Too: Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating. Follow Amy on Instagram @habitwhisperer
In this episode, Dr. Valentin Fuster highlights a groundbreaking study on acoramides, a novel treatment for transthyretin amyloid cardiomyopathy (ATTR), which shows significant reductions in mortality and cardiovascular hospitalizations compared to a placebo. Experts discuss the clinical implications, comparing acoramides to the previously approved tafamidis, noting exciting advancements in treatments for a once-untreatable disease.
CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge. Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques. This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture. Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis. Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications. Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential. The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments. Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived? Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function. In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy. There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR. Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition. Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals. How does aTTR lead to deleterious effects in the heart and other organ systems? Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...
Andrew Frank, MD, BScH, FRCPC - Decoding the Evidence Around Anti-Amyloid Therapies for Alzheimer's Disease: Expert Insights for Clinical Practice
Andrew Frank, MD, BScH, FRCPC - Decoding the Evidence Around Anti-Amyloid Therapies for Alzheimer's Disease: Expert Insights for Clinical Practice
Dr Clíona Farrell, narrating her blog written for the Dementia Researcher website. Explore the lesser-known yet vital aspect of Alzheimer's disease in our latest blog from Clíona. This post gets into the complex world of amyloid-β deposition within the brain's blood vessels. Clíona is embarking on a new postdoc project focused on this area, and in this article she shares insights into how Cerebral Amyloid Angiopathy (CAA) not only coexists with Alzheimer's but also significantly impacts disease pathology and patient outcomes. Discover the implications of recent anti-amyloid therapies and why understanding CAA is crucial for future Alzheimer's treatments. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-a-vascular-element-of-alzheimers-cerebral-amyloid-angiopathy/ -- Dr Clíona Farrell is a Postdoctoral Researcher in the UK Dementia Research Institute at University College London. Her work focuses on understanding neuroinflammation in Down syndrome, both prior to, and in response to, Alzheimer's disease pathology. Originally from Dublin, Ireland, Clíona completed her undergraduate degree in Neuroscience in Trinity College, and then worked as a research assistant in the Royal College of Surgeons studying ALS and Parkinson's disease. She also knows the secret behind scopping the perfect 99 ice-cream cone. @ClionaFarrell_ -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social
Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease.Read the full article:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01883-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this conversation, Dr. Sam Sigoloff interviews Richard Hirschman, a trade embalmer, about the alarming discovery of unusual clots found in deceased individuals, particularly in relation to the COVID-19 pandemic. Hirschman shares his experiences and findings, detailing the characteristics of these clots, their potential links to amyloid proteins, and the implications for public health. The discussion highlights the role of embalmers in uncovering medical anomalies and raises concerns about the broader health impacts of these findings. In this segment of the conversation, Dr. Sam Sigoloff and Richard Hirschman delve into the perplexing phenomenon of clot formation in both veins and arteries, particularly in the context of COVID-19. They discuss the implications of autopsy findings, the unusual presence of amyloid clots, and the potential connections to vaccines. The dialogue also touches on the role of lipid nanoparticles and the broader implications of emergency use authorization in the context of public health and safety. In this conversation, Richard Hirschman and Dr. Sam Sigoloff delve into the alarming discovery of micro-clots in blood samples, potentially linked to vaccines and COVID-19. They discuss the challenges faced in medical research, the erosion of trust in the medical system, and the ethical dilemmas surrounding the reporting of vaccine-related injuries. The dialogue emphasizes the need for further investigation into the causes of these clots and a collective call to action for the medical community and society at large.TakeawaysRichard Hirschman has documented over 200 unusual clots since 2021.The clots are unlike anything seen prior to the pandemic.Amyloid proteins are being found in these clots, raising health concerns.The presence of amyloid in the bloodstream is alarming.There is a potential link between these clots and vaccine injuries.Embalmers are observing changes in blood that are not typical post-mortem clots.The clots are dense and do not fall apart like normal clots.There is a need for further research into the nature of these clots.The conversation highlights the importance of embalmers in medical discoveries.The findings could explain various health issues being reported post-vaccination. Autopsies typically focus on organ examination, not detailed vascular analysis.Clots are usually found in veins, not arteries, raising concerns about new findings.The presence of amyloid in clots suggests a significant change in clot composition post-COVID.Vaccine-induced thrombotic thrombocytopenia is a rare but concerning phenomenon.Lipid nanoparticles may play a role in abnormal clotting mechanisms.Emergency use authorization was declared amidst a perceived attack on public health.The presence of amyloid-like structures in blood raises questions about vaccine safety.Research indicates a potential link between spike proteins and abnormal clotting.The discussion highlights the need for further investigation into vaccine-related health issues.The conversation emphasizes the importance of transparency in medical research and public health policies. There is a significant presence of micro-clots in blood samples.Micro-clots may be linked to a new blood-borne amyloid clotting syndrome.Observation and documentation are crucial in identifying unusual medical phenomena.Medical research faces challenges in funding and peer review processes.Trust in the medical system has been severely impacted by COVID-19 protocols.The correlation between vaccines and abnormal clots is a growing concern.Ethical dilemmas arise when reporting potential vaccine injuries.Not everyone experiences the same reactions to vaccines, but harm does occur.A spiritual perspective is essential in addressing the current health crisis.Community leaders must advocate for truth and transparency in medical practices.lf you like my t-shirt please get one here: XL https://www.ebay.com/itm/166498979030?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYLarge https://www.ebay.com/itm/166498976051?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYMedium https://www.ebay.com/itm/166498969796?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYSmall https://www.ebay.com/itm/166498972939?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYIf you would like to purchase better than grass fed and grass finished beef that will never get mRNA injections, never get growth hormones and never get antibiotics check out mycleanbeef.com/afterhoursAs always please like, share and follow. Please check out my Patreon account (https://www.patreon.com/Afterhourswithdrsigoloff). This is mostly to help with the legal fees. Please consider contributing but if you are unable to donate money please give prayers.truthforhealth.org for COVID illness and long haulers syndrome treatment protocols. If you have a vaccine injury (from any vaccine or have any injury that you think may have any relation to any vaccine) please report in their civilian equivalent to VAERS.Patreon: https://www.patreon.com/Afterhourswithdrsigoloff Email: afterhours@1791.com Instagram: @afterhourswithdrsigoloff Clouthub: @DrSigoloff TruthSocial: @DrSigoloff Rumble: https://rumble.com/c/AfterHoursWithDrSigoloff Youtube: https://www.youtube.com/channel/UCQ_ng3WYVhnctCYq6Rom07g Givesendgo: https://www.givesendgo.com/G37EN
CME credits: 0.50 Valid until: 23-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/time-out-a-case-based-deep-dive-into-the-challenges-of-aria-management/26588/ Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.=
This week, we look at the new pharmaceuticals that the FDA has approved for treating Alzheimer disease. Although they are effective at removing amyloid plaques from the brain, they don't seem to help patients function better. Is it time to turn away from an exclusive focus on amyloid to consider other factors that might affect […]
CME credits: 0.50 Valid until: 19-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/an-overview-of-aria-a-multidisciplinary-crash-course-for-baseline-clinical-needs/26587/ Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.=
Are you up to date on the new developments for emerging therapies for your patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 12/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002007?ecd=bdc_podcast_libsyn_mscpedu
Guest Michael Greicius is an authority on Alzheimer's disease. He makes the case that while effective treatments have remained elusive, there are high hopes for new approaches that target tau proteins in the brain associated with the disease. In the meantime, to reduce Alzheimer's risk stay active, eat well, and manage circulatory risks, but skip genetic testing for now until better treatments emerge, Greicius tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michael GreiciusConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michael Greicius, a professor of neurology and neurological sciences at Stanford University.(00:02:12) Understanding Alzheimer's DiseaseThe roles of amyloid and tau proteins in Alzheimer's disease.(00:04:53) Challenges in Developing TreatmentsThe multiple hurdles in creating Alzheimer's therapies.(00:09:07) Current Alzheimer's DrugsThe controversies and limitations of recently approved drugs.(00:10:23) Amyloid Plaques and Their ImpactWhy removing amyloid plaques hasn't improved patient outcomes.(00:14:29) Problems with Alzheimer's TrialsThe disconnect between amyloid removal and patient outcomes.(00:18:03) Functional Unblinding and Trial BiasHow functional unblinding affects trial results and drug evaluations.(00:23:51) The Potential of Targeting TauNew breakthroughs in targeting tau protein for Alzheimer's.(00:26:35) The Future of PreventionPotential preemptive treatments for Alzheimer's and their administration.(00:29:19) Lifestyle and Risk ReductionRecommendations for reducing risk of Alzheimer's disease.(00:31:43) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate its ability to slow cognitive decline in early-stage Alzheimer's patients and demonstrate the accuracy of biomarkers in identifying pathology before symptoms appear. Eric explains, "We've identified, and this is a monoclonal antibody, a monoclonal antibody with a unique mechanism of action in that it targets what are called Aβ oligomers. And without going into all the details, these Aβ oligomers are now really felt to be the toxic species, the ones that cause the neurons to die, and the two drugs that have recently gotten approval sort of indirectly get at those toxic species, maybe one more than the other. But in our case, we're directly targeting what we think is the most toxic species. And so the progress in the field is wonderful, and nobody can say that it's not, or take anything away from that, but nobody's cured the disease either. Now we know we've got a toehold, we know an approach, and Acumen is using an antibody because of this unique target. We think of it as a next-generation treatment for Alzheimer's disease." "We've known about these Alzheimer's plaques for a long time, but what's more recent is understanding some of these intermediate species. And so these Aβ oligomers we target are oligo, meaning a few. So, anywhere from 2 to 200 of these Aβ stuck together. The Aβs are basically inherently sticky. And so the things we're most interested in are probably 10 of the Aβ together up to say 50, which seems to be the sweet spot." #AcumenPharmaceuticals #Alzheimers #ALZ #EndALZ #Sabirnetug #DrugDevelopment acumenpharm.com Listen to the podcast here
Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate its ability to slow cognitive decline in early-stage Alzheimer's patients and demonstrate the accuracy of biomarkers in identifying pathology before symptoms appear. Eric explains, "We've identified, and this is a monoclonal antibody, a monoclonal antibody with a unique mechanism of action in that it targets what are called Aβ oligomers. And without going into all the details, these Aβ oligomers are now really felt to be the toxic species, the ones that cause the neurons to die, and the two drugs that have recently gotten approval sort of indirectly get at those toxic species, maybe one more than the other. But in our case, we're directly targeting what we think is the most toxic species. And so the progress in the field is wonderful, and nobody can say that it's not, or take anything away from that, but nobody's cured the disease either. Now we know we've got a toehold, we know an approach, and Acumen is using an antibody because of this unique target. We think of it as a next-generation treatment for Alzheimer's disease." "We've known about these Alzheimer's plaques for a long time, but what's more recent is understanding some of these intermediate species. And so these Aβ oligomers we target are oligo, meaning a few. So, anywhere from 2 to 200 of these Aβ stuck together. The Aβs are basically inherently sticky. And so the things we're most interested in are probably 10 of the Aβ together up to say 50, which seems to be the sweet spot." #AcumenPharmaceuticals #Alzheimers #ALZ #EndALZ #Sabirnetug #DrugDevelopment acumenpharm.com Download the transcript here
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
It's too soon to conclude anti-amyloid therapies are safe for use by Alzheimer's patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year's Clinical Trials on Alzheimer's Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look like.BioCentury's editors also assess Phase II data presented at CTAD by UCB that provide some of the first clues about what species of tau to target and in which patients. And they discuss what results of Tuesday's presidential contest in the U.S. will mean for FDA, as well as the state of play for China biotech as the industry continues to grind out its first bear market.View full story: https://www.biocentury.com/article/65407500:00 - Introduction01:23 - CTAD: Anti-amyloids14:22 - CTAD: UCB's tau data19:47 - FDA & the Election28:16 - China Summit DebriefTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Dr. Stephanie welcomes neurophysiologist and former world-class athlete Louisa Nicola. Together, they dive into the critical topic of brain health, with a focus on cognitive decline, dementia, and Alzheimer's disease—conditions that disproportionately affect women. Louisa, founder of NeuroAthletics, brings her expertise in helping athletes and investors optimize their brain function.Episode Overview:0:00 Intro/Teaser3:08 Alzheimer's Disease9:50 The Role of Amyloid and Tau Tangles24:18 Protecting Brain Health Against Alzheimer's28:06 Benefits of Exercise on Brain Health42:16 Strength and Neurocognitive Training52:48 Optimizing Brain Health With Omega-3s56:51 Debunking Myths About Creatine1:01:01 Optimizing Brain Health With Nutrition1:13:36 The Power of Social Relationships1:21:27 Connecting With Louisa Nicola-------------- NOW OPEN! EVEN BETTER! PREMIUM MEMBERSHIP: Subscribe at https://estima.supercast.com/ --------------Resources mentioned in this episode can be found at https://drstephanieestima.com/podcasts/womens-brain-health-cognitive-decline-dementia-alzheimers-with-louisa-nicola/Bio:Louisa Nicola is a neurophysiologist, human performance coach, and the founder of Neuro Athletics, a consulting firm that works with elite athletes and high-level professionals to optimize brain health and performance. With a background as a former world-class triathlete representing Australia, she transitioned into neuroscience, earning her Master of Medicine in neurophysiology from the University of Sydney. Louisa now focuses on helping athletes and investors achieve peak cognitive and physical performance through cutting-edge neuroscience strategies, including EEG scans, lab tests, and cognitive assessments. She is currently pursuing her doctorate, studying the effects of resistance exercise on brain health. Louisa is passionate about optimizing brain function and longevity, particularly in women, by focusing on sleep, nutrition, and exercise.We are grateful to our sponsors:BON CHARGEWhether you're an athlete looking to recover from intense workouts, a muscle mommy looking for some relief from the delayed onset muscle soreness, or just looking for relief from everyday muscle tension, the new Boncharge cold and heat therapy massage gun is your new best friend. Head over to https://BonCharge.com/better and use discount code BETTER at checkout for a 15% discount.TIMELINEFeeling tired and having no energy does not have to be your fate. Mitopure is a supplement and skin health line that helps improve energy at the level of the mitochondria so that you can continue to engage in the activities you love. Go to https://timelinenutrition.com/better and use code BETTER to get 10% off your order.COLDTUREEmbrace the cold with Coldture, the simplest and most fun way to feel the benefit of cold water immersion from the comfort of your home without having to load up ice in the bathtub. Head on over to https://coldture.com/drstephanie and use code DRSTEPHANIE to get an exclusive discount.
On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer's research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on:The impact of molecular diagnostics on Alzheimer's researchRecent Alzheimer's drug approvalsThe future of Alzheimer's research*Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital*Chapters00:00 – Introduction01:54 – Why Sarah began studying Alzheimer's03:39 – Current tools and needs for future Alzheimer's diagnostics09:52 – Recent drug approvals in the Alzheimer's space and their relationship to diagnostics14:26 – Is it possible to develop biomarkers that detect Alzheimer's at its earliest stages?16:36 – What is limiting the development of new Alzheimer's biomarkers?17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer's19:33 – The genetics of Alzheimer's22:19 – Novel approaches to identifying and understanding Alzheimer's pathology 25:54 – Where can proteomics advance Alzheimer's research?31:25 – The role of proteomics in Alzheimer's animal models34:33 – Sarah's hopes for the next 10 years of Alzheimer's research41:39 - OutroResourcesDominant Inherited Alzheimer's Network (DIAN) trials research updateso In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer's disease.Amyloid plaque reducing clinical trials:o Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022)o Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023)o Lecanemab in Early Alzheimer's Disease (Van Duck et al. 2022)Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024)o Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer's diseaseResurrecting the Mysteries of Big Tau (Fischer and Baas 2021)o Review covering a potentially neuro-protective form of tau called “Big tau”Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease (Hurst et al. 2023)o Paper linking the NRN1 protein to cognitive resilience in...
Top tips for informed conversations with patients and their families around this new class of drugs for Alzheimer's disease (AD). Credit available for this activity expires: 10/28/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001764?ecd=bdc_podcast_libsyn_mscpedu
New results suggest the disease progresses differently in women, but we need more basic science to unpack the mechanisms involved.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025.At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
Can Alzheimer's really be optional? Join Dr. Dale Bredesen and Louisa Nicola as they dive into cutting-edge research and practical strategies to prevent cognitive decline. In this eye-opening episode, you'll discover why Alzheimer's doesn't have to be inevitable.Dr. Bredesen reveals the power of proactive steps—like advanced blood tests, genetic risk assessments, and lifestyle changes—that can reshape your brain health. From the role of the APOE gene to inflammation and detoxification, you'll learn how to take control of your cognitive future.If you're ready to challenge the narrative that Alzheimer's is unavoidable, this episode is for you. Timestamps0:00 Alzheimer's Prevention Through Lifestyle and Supplements3:02 Alzheimer's Disease as an Optional Condition Through Early Intervention9:47 Maui Nui Venison Sticks: The Ultimate On-The-Go Protein Snack12:05 Understanding Alzheimer's Disease and Its Underlying Causes15:40 Understanding Alzheimer's as a Network Insufficiency and Its Causes20:53 Metabolic Flexibility and Its Role in Cognitive Health25:47 Lifestyle Factors and Genetic Risks in Alzheimer's Prevention35:27 Inflammation's Role in Alzheimer's and Environmental Impact on Health44:21 Tau and Amyloid as Antimicrobial Peptides in Alzheimer's Disease49:56 Exploring Links Between MS, Alzheimer's, and Immune Responses57:15 Reversing Alzheimer's Through Nutrients, Detox, and Lifestyle Changes1:04:51 Innovations in Brain Health and Alzheimer's PreventionMomentous - Use code NEURO to get 20% off your order - https://www.livemomentous.com/neuroMaui Nui Venison - Use code NEURO to get 20% off https://mauinuivenison.com/pages/NEUROThe Neuro Athletics Newsletter Instagram: @louisanicola_Twitter : @louisanicola_YouTube: @Louisa NicolaThe Neuro Experience Podcast is proud to have hosted: Dr Andrew Huberman, Dr Gabrielle Lyon, Dr Layne Norton, Thomas DeLauer, Shawn Stevenson, Dr. Rocio Salas-Whalen, Saad Alam, Uma Naidoo, Dr. Lanna Cheuck, Angela Lee Pucci, Jillian Turecki, Dr. Jordan Feigenbaum, Dr. Darren Candow, Dr. Sue Varma, Evy Poumpouras, Dr Casey Means, Renee Deehan, Dr Chris Palmer, Dr Charles Brenner, Dr Joe Zundell
In this week's podcast, Neurology Today's editor-in-chief highlights articles on Eastern equine encephalitis relief, systems developed to meet demand for anti-amyloid therapies, and a new protocol for timely diagnosis and treatment for eye stroke in the emergency department. This Podcast is being Sponsored by LocumTenens.com
Dr. Steven DeKosky is professor of Alzheimer's research at the University of Florida College of Medicine and Deputy Director of the McKnight Brain Institute at that institution. He also is a professor of neurology and neuroscience there. Previously, he served as vice president and dean of the University of Virginia School of Medicine and was chairperson of the department of neurology at the University of Pittsburgh. Part 2 For the short-term, with mild to moderate traumatic injury you can have altered synaptic structure and function. For the longer term, chronic inflammation and chronic oxidative stress can lead to subsequent degeneration and also some chronic microglial activation, which may turn on mechanisms that you do not necessarily want, including cleaning up partially injured neurons that may recover. Especially in patients who get the disease in an older age, there is other pathology in the CTE. There are nerve fibrillary tangle and Lewy body. Amyloid beta can be elevated in both white matter and grey matter and might add to the cascade that is thought amyloid leads to, which leads to degeneration especially Alzheimer's disease, but cannot prove it. Participants in contact sports all are at significant risk. APOE 4 increases the risk of Alzheimer's disease and the risk of tau deposition. Currently, when patients arrive for rehabilitation, they are going to have things a lot better described than was the case previously. We can look at disruption of structures, see hemorrhage and inflammation. We know that CTE is not a new disease, but we do see the pathology in other contact sports and we do not view it in autopsy series unless the individual had a history or repetitive head injury. A Question & Answer period followed.
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer's disease. Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.Today's guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer's therapies, as growing biological understanding of Alzheimer's risk and resilience bear fruit with promising new approaches to treatment.Learn More:Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.Amyloid Drug Skepticism:Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies(Commentary, Journal of Alzheimer's Disease, 2024)New Drug Approved for Early Alzheimer's (New York Times, 2024)Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)One step back: Why the new Alzheimer's plaque-attack drugs don't work (Stanford Medicine Scope Blog, 2024)Alzheimer's Genetics Research:Knight-funded research uncovers gene mutations that may prevent Alzheimer's Disease (Knight Initiative for Brain Resilience, 2024)Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)Scientists find genetic Alzheimer's risk factor tied to African ancestry (Stanford Medicine, 2023)Episode CreditsThis episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Dr. Linda Chu speaks with Dr. Giuseppe Esposito, Dr. Yasar Torres-Yaghi, and Dr. Lydia Wood to explore how the availability of amyloid PET imaging and other advanced neuroimaging techniques is transforming the diagnostic and treatment landscape for neurodegenerative disorders. Sponsored by GE HealthCare.
In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer's dementia. Unfortunately, the evidence shows these medications don't seem to have a clinically important effect and do have some harms. Have a listen as we give you […]
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SRN865. CME/MOC/AAPA credit will be available until August 14, 2025.Preparing Specialists for the New Era in Alzheimer's Disease: A Case-Based Exploration of Strategies for Integrating Diagnostic Biomarkers and Amyloid-Targeting Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
In this episode, we break the cycle of societal pressures as we speak with scientist and STEMinist, Chloe Kirk! We chat about finding your place in STEM, choosing a grad school and a lab in grad school, non-traditional STEM careers, the importance of science communication to show everyone belongs in science & how to break stigmas of what a scientist looks like. Listen to Today's Episode to Learn About: -finding the thing that makes you tick -imposter syndrome -fake it till you make it -starting a new career -should tenure exist? -learning from hands on experiences -nothing changes when nothing changes -how to advocate for yourself -what grad school was supposed to be and what it is now -how Chloe merged science and law -networking -listener questions WHO IS CHLOE? From Chloe: “My background is in molecular and cell biology. I recently completed my PhD focusing on a physiological amyloid, Amyloid-bodies, and their roles in cancer and neurodegenerative diseases. My research passion is cell microscopy, but my larger goal is to bring science to more people which is why I am now combining science with law working in patent law!” SYNC UP WITH CHLOE: Instagram and TikTok: @chloe.the.scientist Twitter: @chloeckirk
Why You Should Listen: In this episode, you will learn about a toolkit to improve cognition and protect brain health from cognitive decline. About My Guest: My guest for this episode is Dr. Heather Sandison. Heather Sandison, ND is a renowned naturopathic doctor specializing in neurocognitive medicine and the founder of Solcere Health Clinic, San Diego's premier brain optimization clinic, and Marama, the first residential memory care facility to have the goal of memory recovery. She has dedicated her career to supporting those suffering with dementia and is the primary author of the peer reviewed research “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline” published in the Journal of Alzheimer's Disease. Dr. Sandison hosts the annual online Reverse Alzheimer's summit where she shares cutting-edge and tried-and-true insight into what is possible for those suffering with dementia. She is excited to shatter common misconceptions about Alzheimer's and share what she has learned about keeping your brain sharp at any age. She is also the author of the newly released book “Reversing Alzheimer's The New Toolkit to Improve Cognition and Protect Brain Health”. Key Takeaways: What are the most common factors impacting cognitive health today? What are some of the top tools for mitigating environmental toxicity? What approaches lead to optimal microbiome diversity? What is the role of herpetic viruses in Alzheimer's? How much more important has vascular health become in the pandemic era? What are the genetic contributors to cognitive decline? Is the presence of amyloid correlation or causation? How can one more consistently remain in ketosis without dependence on exogenous ketones? Should certain people avoid saturated fats? What are some of the tools that may assist in balancing lipid dysregulation? Is there a place for limbic and vagal work in optimizing cognitive health? What are some of the common challenges preventing optimal sleep? Are all seed oils toxic? Can vegetarians and vegans optimize cognitive health without animal protein? What is the role of hypercoagulation and arterial calcification in cognitive decline? How important is reducing EMFs in reversing Alzheimer's? How can mitochondrial health be supported to optimize energy currency production? Can antimicrobial mouthwashes actually make things worse? What is the role of peptides in supporting brain health? Connect With My Guest: http://ReversingAlzheimersBook.com Interview Date: June 18, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode202. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer: The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.
June is Alzheimer and brain awareness month. This is a re-release to a podcast episode from December 2022 that focuses on this important topic. Dr. Manisha Bahl interviews Dr. Jeffrey Prescott. Diffuse Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort. Prescott et al. Radiology 2022; 302:143–150.
Welcome back to today's Friday Review where I'll be breaking down the best of the week! I'll be sharing specifics on these topics: Summer Detox Starts Soon! Borgusi Treadmill (product review) The Mountain is You (book review) Beta Amyloid Plaque & Brain Health(research) Sneaky Labeling for Aspartame (research) For all the details tune in to today's Cabral Concept 3052 – Enjoy the show and let me know what you thought! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3052 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
© 2020-2025 Ivy Podcast Discovery LLC
